The Alagille Syndrome market growth is driven by factors like increase in the prevalence of Alagille Syndrome, investments in research and development, entry of emerging therapies during the study period 2019-2032.
The Alagille Syndrome market report also offers comprehensive insights into the Alagille Syndrome market size, share, Alagille Syndrome epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Alagille Syndrome market size growth forward.
Some of the key highlights from the Alagille Syndrome Market Insights Report:
Several key pharmaceutical companies, including Mirum Pharmaceuticals, Lumena Pharmaceuticals, Albireo, and others, are developing novel products to improve the Alagille Syndrome treatment outlook.
The total Alagille Syndrome market size will include the market size of the potential upcoming therapies and current treatment regimens in the seven major markets.
As per DelveInsight analysis, the Alagille Syndrome market is anticipated to witness growth at a considerable CAGR
Strategise your business goals by understanding market dynamics @ Alagille Syndrome Market Landscape
Alagille Syndrome Overview
Alagille syndrome (ALGS) is a rare genetic disorder that can affect multiple organ systems of the body including the liver, heart, skeleton, eyes and kidneys. The specific symptoms and severity of Alagille syndrome can vary greatly from one person to another, even within the same family. Some individuals may have mild forms of the disorder while others may have more serious forms.
Alagille Syndrome Symptoms
The symptoms and severity of Alagille syndrome can vary greatly from one person to another, even among members of the same family. Some individuals may have a mild form of the disorder that can virtually go unnoticed; other individuals may have a serious form of the disorder that can potentially cause life-threatening complications. Alagille syndrome can be associated with abnormalities of the liver, heart, eyes, skeleton, kidneys and other organ systems of the body. A main finding of Alagille syndrome is liver disease that often becomes apparent within the first three months of life. However, individuals with mild liver involvement may not be diagnosed until later in life. Liver disease in Alagille syndrome, if present, may range in severity from jaundice or mild cholestasis to severe, progressive liver disease that can potentially result in liver failure.
Alagille Syndrome Diagnosis
A diagnosis of Alagille syndrome is made based upon identification of characteristic symptoms, a detailed patient history, a thorough clinical evaluation and a variety of specialized tests. Because the symptoms of Alagille syndrome are highly variable, obtaining a diagnosis can be difficult. Surgical removal and microscopic study of liver tissue (liver biopsy) can reveal bile duct paucity. Although bile duct paucity is considered a key characteristic of Alagille syndrome, this finding is not always present in infants with the disorder.
Alagille Syndrome Treatment
The treatment of Alagille syndrome is directed toward the specific symptoms that are apparent in each individual. Treatment may require the coordinated efforts of a team of specialists. Pediatricians, gastroenterologists, cardiologists, ophthalmologists, and other healthcare professionals may need to systematically and comprehensively plan an effect on a child’s treatment. Individuals with Alagille syndrome should have a baseline echocardiogram (ultrasound of the heart) to screen for heart involvement, ultrasound of the abdomen to screen for liver and kidney anomalies, and a screening eye (ophthalmology) exam, In addition, if not previously obtained for specific symptoms, a screening imaging study of the blood vessels of the head (MRI/MRA) is recommended for children who are old enough to sit through the study without need for anesthesia or sedation.
Do you know the treatment paradigms for different countries? Download our Alagille Syndrome Market Sample Report
Alagille Syndrome Epidemiology Segmentation
DelveInsight’s Alagille Syndrome market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Alagille Syndrome historical patient pools and forecasted Alagille Syndrome patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Alagille Syndrome Market report proffers epidemiological analysis for the study period 2019-32 in the 7MM segmented into:
Alagille Syndrome Prevalence
Age-Specific Alagille Syndrome Prevalence
Gender-Specific Alagille Syndrome Prevalence
Diagnosed and Treatable Cases of Alagille Syndrome
Visit for more @ Alagille Syndrome Epidemiological Insights
Recent Breakthroughs in the Alagille Syndrome Market
FDA approves Bylvay for cholestatic pruritus due to Alagille syndrome: The FDA has approved Bylvay for the treatment of cholestatic pruritus due to Alagille syndrome in patients aged 12 months or older, according to an Ipsen Biopharmaceuticals press release.
Alagille Syndrome Treatment Market
The Alagille Syndrome market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Alagille Syndrome market trends by analyzing the impact of current Alagille Syndrome therapies on the market, unmet needs, drivers and barriers, and demand for better technology.
This segment gives a thorough detail of Alagille Syndrome market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Alagille Syndrome market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the Alagille Syndrome market in 7MM is expected to witness a major change in the study period 2019-2032.
Alagille Syndrome Emerging Drugs
Maralixibat: Mirum Pharma
Maralixibat is a novel, minimally absorbed, orally administered investigational drug being evaluated in several rare cholestatic liver diseases. Maralixibat inhibits the apical sodium dependent bile acid transporter (ASBT), resulting in more bile acids being excreted in the feces, leading to lower levels of bile acids systemically, thereby potentially reducing bile acid mediated liver damage and related effects and complications. More than 1,600 individuals have received maralixibat, including more than 120 children who have received maralixibat as an investigational treatment for Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC).
Odevixibat is a highly potent, non-systemic ileal bile acid transport inhibitor (IBATi) that has has minimal systemic exposure and acts locally in the small intestine. Albireo is developing odevixibat to treat rare pediatric cholestatic liver diseases, including progressive familial intrahepatic cholestasis, biliary atresia and Alagille syndrome.
Alagille Syndrome Key Companies
For more information, visit Alagille Syndrome Market Analysis, Patient Pool, and Emerging Therapies
Scope of the Alagille Syndrome Market Report:
11 Years Forecast
Descriptive overview of Alagille Syndrome, causes, signs and symptoms, diagnosis, treatment
Comprehensive insight into Alagille Syndrome epidemiology in the 7MM
Alagille Syndrome marketed and emerging therapies
Alagille Syndrome companies
Alagille Syndrome market drivers and barriers
Key Questions Answered in the Alagille Syndrome Market Report 2032:
What was the Alagille Syndrome market share distribution in 2019, and how would it appear in 2032?
What is the total Alagille Syndrome market size and the market size by therapy across the 7MM for the study period (2019-32)?
What are the important findings from 7MM, and which country will have the greatest Alagille Syndrome market size from 2019-32?
During the study period (2019-2032), at what CAGR is the Alagille Syndrome market projected to expand at 7MM?
Table of Contents:
1 Alagille Syndrome Market Key Comprehensive Insights
2 Alagille Syndrome Market Report Introduction
3 Competitive Intelligence Analysis for Alagille Syndrome
4 Alagille Syndrome Market Analysis Overview at a Glance
5 Executive Summary of Alagille Syndrome
6 Alagille Syndrome Epidemiology and Market Methodology
7 Alagille Syndrome Epidemiology and Patient Population
8 Alagille Syndrome Patient Journey
9 Alagille Syndrome Treatment Algorithm, Alagille Syndrome Current Treatment, and Medical Practices
10 Key Endpoints in Alagille Syndrome Clinical Trials
11 Alagille Syndrome Marketed Therapies
12 Alagille Syndrome Emerging Therapies
13 Alagille Syndrome: 7 Major Market Analysis
14 Attribute analysis
15 Access and Reimbursement Overview of Alagille Syndrome
16 Alagille Syndrome Market Key Opinion Leaders Reviews
18 Alagille Syndrome Market Drivers
19 Alagille Syndrome Market Barriers
20 SWOT Analysis
22 DelveInsight Capabilities
23 About DelveInsight
Alagille Syndrome Epidemiology 2032
DelveInsight’s “Alagille Syndrome – Epidemiology Forecast to 2032” report delivers an in-depth understanding of the disease, historical and forecasted Alagille Syndrome epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Alagille Syndrome Pipeline 2023
“Alagille Syndrome Pipeline Insights, 2023” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Alagille Syndrome market. A detailed picture of the Alagille Syndrome pipeline landscape is provided, which includes the disease overview and Alagille Syndrome treatment guidelines.
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States